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Abstract
Background: In meta-regression, as the number of trials in the analyses decreases, the risk of false positives or
false negatives increases. This is partly due to the assumption of normality that may not hold in small samples.
Creation of a distribution from the observed trials using permutation methods to calculate P values may allow for
less spurious findings. Permutation has not been empirically tested in meta-regression. The objective of this study
was to perform an empirical investigation to explore the differences in results for meta-analyses on a small number
of trials using standard large sample approaches verses permutation-based methods for meta-regression.
Methods: We isolated a sample of randomized controlled clinical trials (RCTs) for interventions that have a small
number of trials (herbal medicine trials). Trials were then grouped by herbal species and condition and assessed for
methodological quality using the Jadad scale, and data were extracted for each outcome. Finally, we performed
meta-analyses on the primary outcome of each group of trials and meta-regression for methodological quality
subgroups within each meta-analysis. We used large sample methods and permutation methods in our meta-
regression modeling. We then compared final models and final P values between methods.
Results: We collected 110 trials across 5 intervention/outcome pairings and 5 to 10 trials per covariate. When
applying large sample methods and permutation-based methods in our backwards stepwise regression the
covariates in the final models were identical in all cases. The P values for the covariates in the final model were
larger in 78% (7/9) of the cases for permutation and identical for 22% (2/9) of the cases.
Conclusions: We present empirical evidence that permutation-based resampling may not change final models
when using backwards stepwise regression, but may increase P values in meta-regression of multiple covariates for
relatively small amount of trials.
Introduction
Systematic reviews are prone to various forms of hetero-
geneity between included studies. Variability in the par-
ticipants, interventions and outcomes across studies may
be termed clinical heterogeneity; variability in the trial
design and quality is typically termed methodological
heterogeneity; variability in treatment effects between
trials can be termed statistical heterogeneity [1,2]. Meth-
odological heterogeneity hinges on the exact methods of
the individual trials, and how they differ from each
other. That is, trials that do not properly conceal alloca-
tion to treatment groups may bias estimates in treat-
ment effect and cause increased variations in effect
between studies included systematic reviews [3]. Signifi-
cant statistical heterogeneity arising from methodologi-
cal heterogeneity suggests that the studies are not all
estimating the same effect due to suffering from differ-
ent degrees of bias [2]. In the current work, we focus on
clinical heterogeneity that arises from differences in par-
ticipant characteristics (for example, sex, age, baseline
disease severity, ethnicity, and so on), types of outcome
measurements, and intervention characteristics (for
example, dose, duration of treatment, form of interven-
tion and so on).
In systematic reviews that assess heterogeneity, this is
typically examined through subgroup analyses or meta-
regression. Subgroup analyses involve dividing the com-
plete dataset into smaller subgroups to make compari-
sons between them. It is suggested that subgroup
analyses be preplanned as part of a systematic review
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protocol, and even then they should be interpreted with
caution [2]. Subgroup analyses may be performed for
subsets of participants (for example, males and females)
or for intervention characteristics (for example, dose or
duration of treatment). These analyses may be per-
formed as a means to investigate heterogeneous results,
to answer questions concerning patient groups, types of
intervention or types of study. However, as more sub-
group analyses are performed on a set of trials, the like-
lihood of finding false positive or false negative results
increases [4].
Meta-regression is an extension of subgroup analyses
that allows continuous as well categorical variables to be
examined and for the investigation of multiple variables
of interest, with the exception of comparisons with less
than 10 trials [4]. Meta-regression is similar to simple
regression in which an outcome variable is predicted
relative to the values of one or more explanatory vari-
ables. The outcome variable in meta-regression is the
effect estimate, and the explanatory variables (that is,
potential effect modifiers or covariates) are any charac-
teristics of the study that might influence the effect esti-
mate. The regression coefficient in meta-regression
describes how the treatment effect changes with each
unit increase in the explanatory variable and the statisti-
cal significance of the coefficient is a test of whether
there is a linear relationship between the two. These
investigations can be misleading for several reasons
[1,2].
First, meta-regression involves making observational
associations that are subject to bias (for example, aggre-
gation bias) and confounding (for example, resulting
from correlation between characteristics). Also, many
systematic reviews using this technique include only a
small number of studies while any one of a large num-
ber of characteristics of these studies could be a cause
of heterogeneity [1,2]. That is, with a smaller amount of
studies, the likelihood of a statistically significant expla-
natory variable rises; a number of false-positive findings
is more likely than in conventional regression [1,2,4].
For these reasons the use of permutation tests have
been suggested to assess the ‘true’ statistical significance
of an observed meta-regression finding for individual
covariates [1,2,4].
The permutation test is useful for analyses of a small
number of studies or a large number of covariates and
has the goal of maintaining the type 1 error rate [4].
Permutation-based resampling tests the hypotheses of
no effect when the distribution of the test statistic is
unknown or when the data are not randomly sampled
from a defined population, as is often the case in pri-
mary meta-analyses or meta-regression [5]. For example,
if we were testing the effect of allocation concealment
on the summary treatment effects, and we want to
compare the summary effect of those trials that per-
formed adequate allocation concealment (group A) and
those that did not (group B), we would test the equality
of the two summary treatment effects (one for A and
one for B) to determine if they likely originated from
the same sampling distribution. For meta-regression the
associated P value is based upon the assumption that
the two statistics were sampled from a normal distribu-
tion. For permutation tests, a covariance matrix, or dis-
tribution, is created for all possible pairs of observations
for groups A and B (total is 32 possible pairs of observa-
tions for 2 groups across 5 pairs of trials, or 32 matrices
and a summary treatment effect difference for each).
Next, a ratio is created relative to the frequency that the
observed difference in treatment effect found in the pri-
mary analysis exceed the overall summary differences
obtained from the permutation analysis resulting in a P
value (for example, 3/32; P = 0.09). A simulation study
has demonstrated that permutation analyses result in
more conservative P values and less false positive rates
than standard meta-regression (when referring to the t
statistic) especially in the presence of heterogeneity,
when there are a small number of studies, or when
there are a large number of covariates [4].
Due to the large number of treatment level covariates
in trials of herbal interventions [6] and the small num-
ber of clinical trials included in systematic reviews of
these interventions [7] it is important to decrease the
false positive rate in meta-regression analyses while still
providing valuable information on which characteristics
of the intervention or other trial characteristics influence
treatment effects. This may lead to increasingly valid
and clinically relevant systematic reviews. With this in
mind, our objective was to explore the differences in
meta-regression modeling results for a predetermined
set of covariates using standard large sample approaches
verses permutation-based resampling methods.
Methods
Trial inclusion
From a sample of 406 randomized controlled trials
(RCTs) of herbal medicine identified through a literature
search reported elsewhere [8], 2 individuals (JJG, HB)
with expertise in herbal medicine interventions identi-
fied a selection of herbal intervention/condition pairings
that would include the largest number of trials for this
project. Through consensus they decided on the follow-
ing pairings: Hypericum perforatum L. (St. John’s wort)
for treating patients with depression, Ginkgo biloba
(ginkgo) for dementia, Serenoa repens (saw palmetto) for
benign prostatic hypertrophy, and Allium sativum (gar-
lic) for blood lipids (triglycerides, lipoproteins and cho-
lesterol). Next, we examined the details of the included
RCTs for each pairing and determined which trials
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included similar outcome measures. All other trials were
excluded from the analyses.
A generally accepted ‘rule of thumb’ is that ten events
per predictor variable (EPV) will maintain bias and
variability at acceptable levels. This guidance derives
from two simulation studies carried out for logistic and
Cox modeling strategies [9-11]. This has been adapted
to meta-regression and thus it is suggested that for each
covariate there should be at least ten trials to avoid
spurious findings [12]. Therefore, we sought to include
a minimum of 20 RCTs for each intervention/outcome
pairing to allow for valid meta-regression with 2 or
more covariates.
Development of intervention level covariates
Next, we identified a variety of intervention level covari-
ates for which to explore heterogeneity. We consulted a
group of four individuals with expertise in RCTs of her-
bal medicine interventions who were asked to identify
characteristics of the herbal medicine interventions that
might influence estimates of treatment effect (for exam-
ple, active constituent levels). The list intervention level
covariates was compiled and included: dose, duration of
use, percentage of active constituent, part of plant used,
form of product (for example, liquid, dried, powder),
method of extraction, and the extraction solvent used.
Methodological quality assessment
Methodological quality was assessed separately and
independently by two individuals. We assessed the
sequence generation, allocation sequence concealment,
blinding, and description of withdrawals and dropouts,
which was the Cochrane practice at the time of this
research [13,14]. Each question was answered with a
yes, no or don’t know response option.
All assessments were entered into preformatted
extraction forms. The assessors met on a weekly basis
to discuss disagreements that were then resolved by
consensus. A third party was not required to resolve any
disagreements.
Data extraction
One individual extracted the following data and a sec-
ond individual checked all extractions: type of interven-
tion, details of the intervention identified above,
summary effect estimates (mean differences, odds ratio
(OR), relative risk (RR), risk difference (RD), no. needed
to treat (NNT), no. needed to harm (NNH)) for the out-
comes of interest, baseline values for the outcomes of
interest in each group, participant levels characteristics
(mean age, proportion of males and females), sample
sizes per group (intention to treat where available), mea-
sures of central tendency for all groups (mean, median,
mode) and measures of variability (SD, SE, range, CI)
before and after treatment on all outcomes of interest,
trial length (in weeks), and year of publication.
Statistical analysis
All statistical procedures were performed by one indivi-
dual (JJG) using STATA 10.0 (Stata, College Station,
TX, USA).
Effect size calculation for individual trials
For each trial, where effect sizes were not reported for
continuous outcome measures we calculated them from
reported means for all outcomes of interest. For contin-
uous variables the effect sizes calculated were mean dif-
ferences (MD) from baseline. All effect estimates for the
outcomes of interest were calculated on intention to
treat (ITT) data where reported. When variance data
were not reported as SDs, they were calculated from the
trial data using the standard error of the mean (SE),
95% confidence intervals, reported P values, ranges or
interquartile ranges according to methods described in
the Cochrane handbook [14]. When trials did not report
information to calculate the variances we imputed
values by giving trials the average SD calculated from
across the other trials.
Meta-analysis for overall effect
The main meta-analysis used a random effects model on
the weighted mean differences (WMD) of the primary
outcome of interest across all trials. We then collected
the WMD, together with 95% CI, P value for the main
effect and I2 results for statistical heterogeneity with the
associated P value. Where measures of variance were
imputed from the average across the other trials, we
performed a sensitivity analysis by removing those trials
and comparing the results with the findings for the ana-
lysis including all trials.
Exploration of heterogeneity
Statistical heterogeneity was detected with Cochran’s Q
test [15,16], which tests if the amount of between trial
heterogeneity is greater than due to chance and the
recently developed I2 statistic measures the magnitude
of statistical heterogeneity that can be expected by parti-
tioning out the chance heterogeneity. Therefore, the
presence of statistical heterogeneity was tested using
Cochran’s Q test [15,16] and the magnitude of statistical
heterogeneity between trials using I2 [1]. An I2 of 0% to
40% will indicate no observed statistical heterogeneity,
30% to 60% moderate heterogeneity, 50% to 90% sub-
stantial heterogeneity, and 75% to 100% considerable
heterogeneity [2].
We performed multivariable meta-regression on the
summary treatment effect for the covariates identified
above, separated into two models for all intervention
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outcome pairings. Covariates representing similar topics
were grouped into models through a small group pro-
cess with the investigators. The first model (model 1)
included methodological covariates (proper randomiza-
tion, proper double blinding, a description of withdrawal
and dropouts (items 2, 4 and 5 of the Jadad scale) and
adequate allocation concealment). The second model
(model 2) included participant level and intervention
level covariates (length of the trial, proportion of males/
females, dose of intervention, baseline severity for the
intervention/treatment group). All categorical covariates
were coded in a binary manner.
We used backwards stepwise elimination in which the
variable with the largest non-significant P value for con-
tribution to the model was dropped and the regression
was repeated. For each model we used standard large
sample methods (referring to the t distribution) and per-
mutation-based resampling to arrive at P values. Vari-
ables were dropped until only significant predictors of
the treatment effect remained. To maintain model valid-
ity, if a binary coded categorical variable was statistically
significant, both categories of the variable were kept in
the model. Collinear variables were also dropped from
the model and explored individually for significance.
Statistically significant P values were those less than
0.05. We then compared the final models and models
obtained with each method.
In the permutation test we tested the equality of two
means: Ho:ux = uy. The assumption being if × data are
sampled from the distribution Px and the Y data from
Py then under the null hypothesis all permutations of
observations are equally probable. The test statistic was
the WMD from the meta-analysis results above on all
levels of the covariates across trials. We then estimated
the null distribution for the treatment effect by permut-
ing (randomly shuffling) the observations in the com-
bined × and Y samples to create all possible
distributions. We then compared the effect estimate (or
difference in effect) obtained with meta-regression for
each covariate against the permuted distribution of
effects to arrive at a P value. All permutations were set
at 10,000 shuffles for each analysis and were performed
simultaneously across all variables.
Results
A total of 110 trials were included in our analyses (see
Figure 1). The intervention outcome pairings are
described in Table 1. All other intervention outcome
pairings had less than 20 trials and thus were not
included. The primary meta-analyses for each of the
pairings are listed in Table 2. For all analyses there was
a statistically significant effect in favor of the herbal
medicine intervention. We also ran a sensitivity analysis
removing those trials for which standard deviations
were imputed. Results of the sensitivity analyses did not
appear to differ from the analyses with all trials
included. In the primary analysis there was statistically
significant heterogeneity for all analyses with I2 values
ranging from 65.7% to 99.1%.
Many of the intervention level covariates were not
reported in the included trials. Also, in no instance did
a trial report enough information to code a trial as per-
forming inadequate allocation concealment. Therefore,
this variable was coded in a binary manner (1 = ade-
quate allocation concealment; 0 = not enough informa-
tion reported in the trial). For the backward stepwise
meta-regression procedures, the covariates remaining in
the final models were identical for large sample techni-
ques and for permutation-based resampling methods of
arriving at P values. Out of a total of ten backwards
stepwise procedures, six of the models for both large
sample methods and permutation-based resampling
resulted in several significant covariates in the final
models. Only the models for low-density lipoprotein
(LDL)-A. sativum (garlic) and for total cholesterol (TC)-
A. sativum resulted in no covariates remaining signifi-
cant. The P values and I2 of the backwards stepwise
elimination procedure for large sample methods (refer-
ring to the t table) and the corresponding P values using
permutation-based resampling including are listed in
Tables 3, 4, 5. The P values for the covariates in the
final model were larger in 78% (7/9) of the cases for
permutation and identical for 22% (2/9) of the cases.
For the Hypericum perforatum (St. John’s wort)-
Hamilton Depression scale (HAM-D) pairing, the back-
ward stepwise elimination meta-regression and permuta-
tion P values are listed in Table 3. All P values obtained
with the permutation tests exceeded those obtained with
standard meta-regression. The stepwise elimination
meta-regression and permutation P values for the influ-
ence of covariates on the effect of Allium sativum on
high-density lipoprotein (HDL) are listed in Table 4.
None of the methodological variables reached signifi-
cance in the first model. In the second model for parti-
cipant level and intervention level covariates both P
values obtained with permutation were identical to
those obtained with standard large sample meta-regres-
sion. This analysis yielded the smallest I2 value (45.8%)
of all stepwise elimination values in all models. The
stepwise elimination meta-regression and permutation P
values for the effect of covariates on changes in trigly-
ceride (TG) for Allium sativum are listed in Table 5. All
P values for permutation were larger than those
obtained with large sample methods.
In Table 6 we present various features of the final
meta-regression models including the number of trials
per variable, the magnitude of statistical heterogeneity
(I2), and the P values for both the large sample methods
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and permutation-based resampling. In the model exhi-
biting moderate levels of statistical heterogeneity (that
is, 45.8%; A. sativum-HDL: model 2), and with an ade-
quate number of trials per variable (that is, 9.5) both
methods of arriving at P values produce identical values.
Discussion
Approximately 50% of systematic reviews use statistical
techniques to combine study results and most of these
assess consistency across the studies [17]. Several studies
report that tests of presence of heterogeneity are fre-
quently performed in meta-analyses, that they are often
statistically significant, and that a variety of methods are
used to explore heterogeneity, including subgroup ana-
lyses and meta-regression [18-21]. Meta-regression may
produce spurious findings when performed on a small
number of studies, or when investigating multiple cov-
ariates [4].
Our study found that using backwards stepwise meta-
regression with large sample methods or with permuta-
tion-based resampling resulted in identical final models.
To the best of our knowledge this is the first empirical
test of permutation in meta-regression modeling using
an elimination procedure. The results are surprising
given that we only had 5 to 6.25 trials per covariate in
all of the initial models, which is well below the recom-
mended 10 trials per variable [9-12]. Given that this rule
of thumb was derived from simulations for logistic and
Cox modeling it is possible that these results do not
reliably apply to meta-regression procedures on continu-
ous outcome variables. For example, a simulation study
on using linear and logistic regression resulted in a rule
3567 titles and 
abstracts isolated and 
reviewed
406 trials reviewed for 
similar 
intervention/outcome 
2329 trials excluded 
for the following 
reasons: Not an RCT,  
herbal medicine, or  
involving human 
participants, non-
English, or being a 
brief report 
832 papers 
excluded due to 
being duplicates of 
trials from 
MEDLINE search
110 trials included
Figure 1 Flow chart of inclusion of trials.
Table 1 Description of included intervention condition
pairings
Herbal intervention Outcome measure Number of RCTs
Hypericum perforatum HAM-D 22
Allium sativum TC 25
Allium sativum LDL 20
Allium sativum HDL 21
Allium sativum TG 22
HAM-D = Hamilton Depression Scale score; HDL = high-density lipoprotein;
LDL = low-density lipoprotein; RCT = randomized controlled trial; TC = total
cholesterol; TG = triglycerides.
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of thumb being proposed that, to avoid overfitting when
using forward stepwise selection procedures, an event
per variable of greater than 4 is required [22-25]. If we
extend this observation to linear meta-regression with a
backwards stepwise selection procedure then our results
seem to make empirical sense. Furthermore, we recom-
mend that more simulations be performed to test the
ten trials per variable rule of thumb.
We also found that the P values obtained using per-
mutation tests are more conservative, or larger, than P
values obtained using standard meta-regression meth-
ods. Specifically, the P values for significant covariates
obtained with stepwise meta-regression were larger with
permutation 78% of the time and identical 22% of the
time compared with using standard large sample meth-
ods of obtaining P values. This finding is particularly
important when P values are near a set level of statisti-
cal significance (for example, 0.05 or 0.01), since any
increase in the P value will render the result non-signifi-
cant. This finding provides empirical evidence that per-
mutation tests increase P values and that permutation
can be used in meta-analyses especially when examining
the effects of multiple covariates, when faced with a
relatively small number of included primary studies, or
when a large amount of statistical heterogeneity is pre-
sent. However, these results do not indicate that permu-
tation-based resampling protects against associations
arising due to ecological bias. One must always be
aware that some associations found at the group level,
in this case the study level, may not apply at the indivi-
dual level.
Our findings are similar to those of Higgins and
Thompson [4] who found that when examining multiple
covariates in a random effects analysis, permutation
resulted in generally larger P values, but not in all
instances. For example, they found that for the covariate
‘intention to treat analysis’ the P value obtained by
meta-regression was larger than that found with permu-
tation. We found that out of nine significant covariates
the P values for seven of these were larger in the per-
mutation tests. In the other two instances the P values
were identical. It is possible that the relatively low het-
erogeneity found in the latter final model (45.8%), or the
relative normality of the distribution of effects in the
final model resulted in this finding. It is possible that
the level of statistical heterogeneity plays a larger role
than the number of trials in meta-regression. This
hypothesis remains to be tested.
Meta-regression may result in spurious findings with
either multiple covariates, with a small number of pri-
mary studies [4,25-28] or when there is a large magni-
tude of statistical heterogeneity. Permutation tests quell
P values when exploring heterogeneity in these circum-
stances and will lead to more conservative probability
estimates. In some cases the P value may cross over to
non-significance. This finding is important in meta-ana-
lytic research especially since meta-analyses often
include a small number of primary studies [4,15],
Table 2 Results of primary meta-analyses and sensitivity analyses
Intervention outcome
pairing
Primary analysis main effect, (95% CI); N trials; I2
(%)
Sensitivity analysis main effect, (95% CI); N trials; I2
(%)
Hypericum perforatum-HAM-D WMD = -3.43 (-4.6 to -2.25); 22ab; I2 = 84.7% WMD = -3.61 (-4.14 to -3.07); 13ab; I2 = 87.7%
Allium sativum-TC WMD = -8.95 (-9.65 to -8.25); 25ab; I2 = 99.1% WMD = -9.27 (-9.98 to -8.56); 19ab; I2 = 99.3%
Allium sativum-LDL WMD = -4.99 (-5.4 to -4.59); 20ab; I2 = 65.7% WMD = -5.05 (-5.45 to -4.64); 13ab; I2 = 96.4%
Allium sativum-HDL WMD = 1.15 (1.05 to 1.25); 21ab; I2 = 77.7% WMD = 1.15 (1.05 to 1.25); 11ab; I2 = 86.4%
Allium sativum-TG WMD = -15.78 (-17.30 to -14.24); 22ab; I2 = 98.4% WMD = -15.72 (-17.34 to -14.09); 10ab; I2 = 99.2%
aP < 0.001 for the main effect.
bP < 0.001 for Cochran’s Q test.
HAM-D = Hamilton Depression Scale score; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TC = total cholesterol; TG = triglyceride; WMD =
weighted mean differences.
Table 3 Hypericum perforatum HAM-D pairing stepwise elimination results: comparison of final P values for final
models using both large sample and permutation techniques
Model Meta-regression (t-distribution), P value Permutation test, P value
1. Methodological covariates:
Appropriate randomization 0.035 0.041
Heterogeneity (I2) 81%
2. Participant level and intervention level covariates:
Length of trial 0.021 0.022
Sex proportion (male) 0.041 0.045
Heterogeneity (I2) 79%
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included studies often fail to report important informa-
tion for these analyses [19], and they often have signifi-
cant statistical heterogeneity [28-30]. The ability to
accurately explore the reasons for heterogeneity and the
influence of specific covariates could create increasingly
specific and clinically relevant findings in meta-analyses
and lead to valid hypothesis generation for future clini-
cal trials. This could potentially save many resources
including time, healthcare expenditure, and funding allo-
cation. In agreement with previous recommendations [4]
it is advised that permutation tests be used in all meta-
analyses that include a small number of clinical trials
per covariate (five or less to ten) or that have consider-
able or substantial heterogeneity.
This study has several strengths. First, we included a
large number of primary studies and crosschecked the
data extractions. By including a large number of studies
we have performed an empirical test of permutation,
which goes beyond previous simulations [4]. Next, we
used a set of covariates that have empirical and theoreti-
cal relationships with our outcome variables. For exam-
ple, it is well known that adequate randomization
sequence generation and allocation concealment are
important predictors of effect size [2,3,29,30]. Also, it
follows from basic pharmacokinetics that differing doses
of the active herbal medicine or its active constituent
predict clinical responses [10]. An additional strength of
this study was that we ran 10,000 iterations in the per-
mutation tests. Given that permutation tests are random
processes, a larger number of permutations results in
very similar findings with each additional permutation
using the same variable. Therefore, our permutation test
P values are likely robust. Another strength of this study
is that it extends the statistical techniques that can be
used in meta-analyses, giving reviewers an empirically
validated method when analyzing the influence of
covariates.
A drawback of this study is that it may not include all
RCTs examining the herbal medicine outcome pairings
chosen. That is, the treatment effect estimates presented
in Table 2 may not be ‘true’ estimates of the effect
across all published trials. We did not set out to per-
form a comprehensive meta-analysis on each pairing or
to describe the actual or true extent/degree of bias or
influence for certain covariates on summary effect esti-
mates. Our objective was to explore the difference in P
values obtained from standard meta-regression and per-
mutation tests on a sample of trials for several covari-
ates. This project was in effect an empirical exercise
comparing two separate statistical techniques for arriv-
ing at P values. Another potential drawback of this
study was that at no point did the permutation test
change a significant P value to a non-significant one.
Even though we did not see this, this would be expected
since in most instances the permutation P value
exceeded the meta-regression values. It is conceivable
that such P value increases would result in a marginally
significant P value obtained with meta-regression to
become non-significant with permutation [4]. Also,
though P values are often used to determine the exis-
tence of covariate-based effect modification, one should
be certain to complement P values with actual differ-
ences in the effects estimates to determine if changes in
the effect are clinically significant. Further research
could build upon the intersection of statistical and clini-
cal significance in effect modification. Finally, the last
Table 4 Allium sativum high-density lipoprotein (HDL) stepwise elimination: comparison of final P values for final
models using both large sample and permutation techniques
Model 2: participant level and intervention level covariates (N = 19) Meta-regression (t-distribution), P value Permutation test, P value
Mean age of participants 0.003 0.003
Baseline HDL of control group < 0.001 < 0.001
Heterogeneity (I2) 45.8%
Table 5 Allium sativum triglyceride (TG) stepwise elimination: comparison of final P values for final models using both
large sample and permutation techniques
Model Meta-regression (t-distribution), P value Permutation test, P value
1. Methodological covariates (N = 22):
Appropriate blinding 0.033 0.047
Heterogeneity (I2) 98.1%
2. Participant level and intervention level covariates (N = 17):
Length of trial 0.001 0.003
Control group TG baseline 0.008 0.016
Dose of garlic 0.031 0.036
Heterogeneity (I2) 87.0%
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drawback of this research was that data from eight trials
for the SJW depression pairing were extracted from
Cochrane reviews [31,32]. Therefore, any errors in
extraction in the Cochrane review will result in errors in
our extractions and the resulting data analyses we
present.
Conclusions
In summary, given that systematic reviews frequently
contain a small number of studies and often wish to
explore the influence of covariates to explain heteroge-
neity, the permutation test may help to protect against
spurious findings when using meta-regression. However,
the changes in significance level we found for the per-
mutation test in the sample of trials we included were
small. Furthermore, the relationship between the magni-
tude of statistical heterogeneity, events per variable and
meta-regression with permutation-based resampling
should be explored in future research.
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